Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Iterum Therapeutics plc
Industry Sector: HealthTechnology
CEO: Corey N. Fishman
Number Of Employees: 9
Enterprise Value: $56,343,687
PE Ratio: -0.89
Exchange/Ticker 1: NASDAQ:ITRM
Exchange/Ticker 2: N/A
Latest Market Cap: $40,460,200
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Nov 9, 2024
Data Byte
FDA’s October approvals include the first CLDN18.2 mAb
Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products
BioCentury | Sep 6, 2024
Data Byte
Advisory committee meetings on FDA’s September docket
Up for discussion are a new antibiotic, Ocaliva’s conversion to full approval, and whether to require PD-L1 as biomarker in certain solid tumors
BioCentury | Jul 27, 2021
Product Development
July 26 Quick Takes: Denali dips on Hunter syndrome readout
Plus: GSK, BMS, PerkinElmer-BioLegend and more
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | Jul 3, 2021
Deals
July 2 Quick Takes: PE firms swap Parexel in $8.5B takeout; plus Arrowhead, Cerevel, Iterum, Caribou, Beneluxa Initiative
EQT Private Equity and Goldman Sachs Asset Management’s PE unit acquired CRO Parexel International Corp. from Pamplona Capital Management. In another reminder that safety risks take time to
BioCentury | Jul 2, 2021
Product Development
July 2021 PDUFA dates: Data Byte
At least seven therapies have PDUFA dates in the month of July, five of which have been granted priority review by FDA. FDA is slated to announce its first decision of the month on Friday on a
BioCentury | Apr 13, 2021
Product Development
FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead
Shares of Provention Bio Inc. (NASDAQ:PRVB) regained a small bit of the ground they lost Friday, when the stock tumbled 18% to $8 after the company revealed FDA wants more data on its BLA for
BioCentury | Jan 26, 2021
Regulation
Jan. 25 Quick Takes: Comirnaty approved in Australia, authorized in Hong Kong; plus Albireo, Iterum and AZ
Comirnaty (BNT162b2) from BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) received provisional approval from the Australian Therapeutic Goods Administration and emergency use authorization
BioCentury | Dec 11, 2019
Clinical News
Iterum antibiotic fails in Phase III for intra-abdominal infections, further driving down shares
Items per page:
1 - 10 of 18